1. CGON presents data for cretostimogene at 2025 Urological Association Meeting. 2. 75.5% complete response seen in high-risk NMIBC patients. 3. 97.3% of patients were free from disease progression at 24 months. 4. No serious treatment-related adverse events were reported. 5. CGON stock surged 39.9% to $31.30 following this news.
The significant efficacy data reported suggests strong market potential, similar to prior successful cancer therapies. Historically, similar trial results have led to substantial price gains for biotech companies due to increased investor confidence.
The reported efficacy and safety profile directly enhances CGON’s market position and investor interest. Strong clinical data in oncology often drives considerable investment interest, as evidenced by historical trends.
Immediate investor sentiment will likely turn positive, reflected in the rising stock price. Market reactions to such clinical data typically manifest within weeks to months.